Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives

Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with impro...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Amm, Joelle, Nassabein, Rami, Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513839/
https://www.ncbi.nlm.nih.gov/pubmed/28744160
http://dx.doi.org/10.2147/CMAR.S139305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513839/
https://www.ncbi.nlm.nih.gov/pubmed/28744160
http://dx.doi.org/10.2147/CMAR.S139305

Ejemplares similares